Targeting mutant p53 through the mevalonate pathway

Nature Cell Biology 18, 1122 (2016).
doi:10.1038/ncb3435

Authors: William Freed-Pastor & Carol Prives
It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.

Source: Nature Cell Biology - October 26, 2016 Category: Cytology Authors: William Freed-Pastor Carol Prives Tags: News and Views Source Type: research